Insulin Glargine "All to Target" Trial

Completed · Phase 4

Conditions studied: Diabetes Mellitus, Type 2

In brief

The primary objectives were: * To demonstrate the superiority of Lantus plus stepwise addition of mealtime Apidra® (Lantus/Apidra-3) versus twice-daily Premixed insulin based on the proportion of patients achieving target glycemic control (as measured by hemoglobin A1c \[HbA1c\] \<7.0%) at Week 60 * To demonstrate the noninferiority of Lantus plus addition of 1 mealtime Apidra injection (Lantus/Apidra-1) versus twice-daily Premixed insulin based on the reduction from Baseline to Week 60 in HbA1c

Key facts

Study ID

NCT00384085

Run by

Sanofi

People needed

588

Starts

2006-05-01

Expected to finish

2010-03-01

Last updated by the study team

2011-05-06

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sanofi-Aventis Administrative Office — Bridgewater, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.